The Role of Circulating Tumour Cells and Carcinoembryonic Antigen as Diagnostic Tool for Metastatic Colorectal Cancer in Indonesia
DOI:
https://doi.org/10.24871/2632025245-254Keywords:
Metastatic colorectal cancer, circulating tumour cell, carcinoembryonic antigen, cacner surveillanceAbstract
Background: Patients with metastatic colorectal cancer (CRC) have a poor prognosis, with a 5-year survival rate of only 14%. Early detection and early intervention may improve outcome. Both circulating tumour cells (CTC) and serum carcinoembryonic antigen (CEA) have been suggested as diagnostic biomarkers for metastatic CRC. This study explored the performance of CTC and CEA as a tools for the detection of metastatic colorectal cancer in Indonesia.
Methods: This study was conducted from December 2024 to April 2025 on metastatic colorectal cancer patients from three hospitals in Jakarta. CTC was analysed using the gradient density method and flow cytometry. CEA was analysed using chemiluminescent microparticle immunoassay.
Results: This study recruited 160 patients with colorectal cancer patients of whom, 45% were known to have metastatic colorectal cancer. The median age was 57 (47—66) years and analysis was done at one time point only. The area under the curve (AUC) for CTC, CEA, and the combination of both CTC and CEA in diagnosing metastatic colorectal cancer was 0.579, 0.811, and 0.703, respectively. CTC showed 56.94% sensitivity and 50.00% specificity in detecting metastatic colorectal cancer. Meanwhile, CEA showed higher sensitivity (72.22%) and specificity (72.72%). Combination of both CTC and CEA increased sensitivity to 91.67%, but with a lower specificity of 37.50%. The optimal cut-off for CTC and CEA were 34.5 cells/3 ml and 18.31 ng/ml, respectively.
Conclusion: CEA showed a better performance than CTC in diagnosing metastatic colorectal cancer. Combination of CTC and CEA showed promising potential as a valuable surveillance tool for detecting metastasis in colorectal cancers, but not as a primary diagnostic tool.
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394-424.
Ionescu VA, Gheorghe G, Bacalbasa N, Chiotoroiu AL and Diaconu C. Colorectal cancer: From risk factors to oncogenesis. Medicina (Kaunas) 2023; 59 (9).
Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu RH, et al. Pan-asian adapted esmo clinical practice guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. ESMO Open 2023; 8 (3): 101558.
Patelli G, Vaghi C, Tosi F, Mauri G, Amatu A, Massihnia D, et al. Liquid biopsy for prognosis and treatment in metastatic colorectal cancer: Circulating tumor cells vs circulating tumor DNA. Target Oncol 2021; 16 (3): 309-24.
Kimman M, Norman R, Jan S, Kingston D and Woodward M. The burden of cancer in member countries of the association of southeast asian nations (asean). Asian Pac J Cancer Prev 2012; 13 (2): 411-20.
Jeo W and Subrata F. The survival rate of colorectal cancer in dr. Cipto mangunkusumo hospital. New Ropanasuri J Surg 2020; 5 (2): 4.
Liu X, Lan H, Yang D, Wang L and Hu L. Prognostic value of circulating tumor cells in patients with recurrent and metastatic colorectal cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2024; 103 (1): e36819.
Rahbari NN, Bork U, Kircher A, Nimitz T, Schölch S, Kahlert C, et al. Compartmental differences of circulating tumor cells in colorectal cancer. Ann Surg Oncol 2012; 19 (7): 2195-202.
Yang CY, Lin CC, Huang SC, Lu RH, Lo LC, Tseng JY, et al. Enhanced prognostic value of combined circulating tumor cells and serum carcinoembryonic antigen in patients with colorectal cancer. J Chin Med Assoc 2023; 86 (5): 465-71.
Chiu SY, Hsieh CH, You JF, Chu PY, Hung HY, Chu PH, et al. Enhancing prediction performance by add-on combining circulating tumor cell count, cd45(neg) epcam(neg) cell count on colorectal cancer, advance, and metastasis. Cancers (Basel) 2021; 13 (11).
He Y, He X, Zhou Y and Luo S. Clinical value of circulating tumor cells and hematological parameters in 617 chinese patients with colorectal cancer: Retrospective analysis. BMC Cancer 2023; 23 (1): 707.
Liu G, Zhu J, Zhang P, Zhang T, Cui Z, Jiao F, et al. Exploring the diagnostic and prognostic significance of circulating tumor cells in stage ii-iv colorectal cancer using a nano-based detection method. J Chin Med Assoc 2024; 87 (10): 945-52.
Petrik J, Verbanac D, Fabijanec M, Hulina-Tomašković A, Čeri A, Somborac-Bačura A, et al. Circulating tumor cells in colorectal cancer: Detection systems and clinical utility. Int J Mol Sci 2022; 23 (21).
Saadi S, Aarab M, Tabyaoui I and Jouti NT. Circulating tumor cells in colorectal cancer - a review of detection methods and clinical relevance. Contemp Oncol (Pozn) 2023; 27 (3): 123-31.
Ding R, Chen Z, He M, Cen H, Liu Z and Su Y. Application value of combined detection of nlr, pni, d-dimer, cd3(+) t lymphocytes, and cea in colorectal cancer screening. Dis Markers 2022; 2022: 7913025.
Luo S, Ou Y, Zheng T, Jiang H, Wu Y, Zhao J, et al. Optimal strategy for colorectal cancer patients' diagnosis based on circulating tumor cells and circulating tumor endothelial cells by subtraction enrichment and immunostaining-fluorescence in situ hybridization combining with cea and ca19-9. J Oncol 2021; 2021: 1517488.
Tao XY, Li QQ and Zeng Y. Clinical application of liquid biopsy in colorectal cancer: Detection, prediction, and treatment monitoring. Mol Cancer 2024; 23 (1): 145.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).










